Previous 10 | Next 10 |
CUPERTINO, Calif., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous...
2023-11-16 08:30:43 ET More on Reviva Pharmaceuticals Reviva Pharmaceuticals: Positive Results In Phase 3 But The Stock Is Back Where It Started Reviva Pharmaceuticals: A Binary Event Approaches With Results From RECOVER Reviva posts late-stage data for schizophrenia...
2023-11-16 08:25:47 ET Losers: Augmedix ( AUGX ) -25% announces proposed public offering of 5.5M shares of common stock. Velo3D ( VLD ) -18% on revising Q3 revenue lower , EPS drops to $0.09 Childrens Place ( PLCE ) -17% after Q3 earning relea...
CUPERTINO, Calif., Nov. 16, 2023 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous...
2023-11-14 17:16:18 ET More on Reviva Pharmaceuticals Reviva Pharmaceuticals: Positive Results In Phase 3 But The Stock Is Back Where It Started Reviva Pharmaceuticals: A Binary Event Approaches With Results From RECOVER Reviva posts late-stage data for schizophrenia...
- RECOVER global Phase 3 trial successfully met all primary and secondary endpoints with statistically significant and clinically meaningful reductions across all major symptom domains at week 4 with 50 mg of brilaroxazine vs. placebo in schizophrenia – - Consistent Phase 3 RECOV...
INVO BioScience Inc. (INVO) is expected to report for Q3 2023 HIVE Blockchain Technologies Ltd (HIVE) is expected to report $-0.13 for Q2 2024 BioNexus Gene Lab Corp (BGLC) is expected to report for Q1 2024 Adhera Therapeutics Inc (ATRX) is expected to report for Q1 2024 Altus Pow...
Reviva Pharmaceuticals Holdings Inc. (RVPH) is expected to report $-0.35 for Q3 2023
2023-11-02 03:11:38 ET Summary Results from the phase 3 RECOVER study of Reviva Pharmaceuticals' antipsychotic brilaroxazine in schizophrenia show that the 50 mg dose beat placebo on the primary endpoint. The 15 mg dose of brilaroxazine was numerically superior to placebo on the p...
2023-10-31 08:17:59 ET Mersana Therapeutics ( MRSN ) +21% Announces FDA has Lifted Clinical Hold on Phase 1 Clinical Trial of XMT-2056. Pinterest ( PINS ) +16% soars as Wall Street is impressed with turnaround strategy. Wolfspeed ( WOLF ) +13%...
News, Short Squeeze, Breakout and More Instantly...
Reviva Pharmaceuticals Holdings Inc. Company Name:
RVPH Stock Symbol:
NASDAQ Market:
Reviva Pharmaceuticals Holdings Inc. Website:
- Patent covers brilaroxazine use for treating pulmonary hypertension (PH), pulmonary arterial hypertension (PAH) in any patients including treating PH in patients with chronic obstructive pulmonary disease (COPD) or sickle cell disease (SCD) -Similar patents have also been granted in k...
2024-06-11 08:15:03 ET H.C. Wainwright analyst issues BUY recommendation for RVPH on June 11, 2024 06:40AM ET. The previous analyst recommendation was Buy. RVPH was trading at $1.45 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current ...
CUPERTINO, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous ...